Fcgamma receptor 1 (CD64), a target beyond cancer.

Thepen, T; Huhn, M; Melmer, G; Tur, M K; Barth, S

Thepen, T; Huhn, M; Melmer, G; Tur, M K; Barth, S.

Affiliation

Thepen T; Fraunhofer Institute for Molecular Biology and Applied Ecology, Department of Pharmacetical Product Development, 52074 Aachen, Germany. Thepen@molbiotech.rwth-aachen.de

Curr Pharm Des ; 15(23): 2712-8, 2009.

Article in En | MEDLINE | ID: mdl-19689341

Subject(s)

Drug Delivery Systems/methods; Immune System Diseases/drug therapy; Immunotoxins/therapeutic use; Inflammation/drug therapy; Receptors, IgG/drug effects; Animals; Humans; Leukemia, Myeloid, Acute/drug therapy; Macrophage Activation/drug effects; Macrophage Activation/immunology; Monocytes/drug effects; Monocytes/immunology; Monocytes/metabolism; Receptors, IgG/immunology; Receptors, IgG/metabolism; Recombinant Proteins/biosynthesis; Recombinant Proteins/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Immunotoxins / Drug Delivery Systems / Receptors, IgG / Immune System Diseases / Inflammation Limits: Animals / Humans Language: En Journal: Curr Pharm Des Journal subject: FARMACIA Year: 2009 Document type: Article Affiliation country: Germany Country of publication: United Arab Emirates

Search on Google

Add to My VHL

XML

PubMed Links